French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.
After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials. Sumitomo ...
Aethyr Research has released post-quantum encrypted IoT edge node firmware for ESP32-S3 targets that boots in 2.1 seconds and ...
On March 31, 2026, the popular HTTP client Axios experienced a supply chain attack, causing two newly published npm packages ...
In 2026, choosing an AI track is mostly a decision about outcomes. GenAI programs help you ship faster workflows and software ...
BACKGROUND: Medically tailored meals (MTM) have unanswered implementation questions. Providing MTM for a specific individual, ...
All in all, your first RESTful API in Python is about piecing together clear endpoints, matching them with the right HTTP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results